Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D. Benson, Teresa Coelho, Márcia Waddington‐Cruz et al.|New England Journal of Medicine|2018Cited by 1.4k
Volanesorsen and Triglyceride Levels in Familial Chylomicronemia SyndromeJoseph L. Witztum, Éric Bruckert, Handrean Soran et al.|New England Journal of Medicine|2019Cited by 663
Antisense Inhibition of Apolipoprotein C-III in Patients with HypertriglyceridemiaDaniel Gaudet, John J.P. Kastelein, Veronica Alexander et al.|New England Journal of Medicine|2015Cited by 526
Targeting APOC3 in the Familial Chylomicronemia SyndromeDaniel Gaudet, Joseph L. Witztum, Diane Brisson et al.|New England Journal of Medicine|2014Cited by 492
AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancerDavid S. Hong, A. Robert MacLeod, Razelle Kurzrock et al.|Science Translational Medicine|2015Cited by 438